The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest ...

(NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United ...

1Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China. 2Department of Cell Biology, Zhejiang University School of Medicine, ...

Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment ...

The study involved in vitro assays and in vivo mouse models to evaluate the efficacy of these modified CAR-T cells. Results demonstrated that the armed CAR-T cells exhibited significantly stronger ...

Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in patients with resected colorectal cancer (CRC). Among a cohort of ...